Workflow
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
SPRYARS Pharmaceuticals(SPRY) GlobeNewswire·2025-03-20 11:00

7.3millionintotalneffy®(epinephrinenasalspray)U.S.netproductrevenuein2024sincelaunchinlateSeptember2024neffy1mgapprovedbyU.S.FDAforchildrenagedfourandolderandweighing15kilogramsto<30kilograms(33lbs.to<66lbs.),expandingthereachofneffytoapproximately2millionyounger,school−agedchildrenatriskofasevereallergicreaction7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing 15 kilograms to < 30 kilograms (33 lbs. to < 66 lbs.), expanding the reach of neffy to approximately 2 million younger, school-aged children at risk of a severe allergic reaction 314.0 million in cash, cash equivalents, and short-term investments at year-end 2024, supporting an increased investment in commer ...